Breaking News, Financial News

BioNTech Revenues Triple in the First Quarter

Increase in commercial revenues from the supply and sales of the company's COVID-19 vaccine more than triple earnings.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

BioNTech 1Q Revenues: €6.4 billion (up from €2.0 billion 1Q21) 1Q Earnings: €3.7 billion (up from €1.1 billion 1Q21) Comments: Growth in the quarter due to increased commercial revenues from the supply and sales of the company’s COVID-19 vaccine worldwide. Under the collaboration agreements, territories have been allocated between BioNTech, Pfizer and Fosun Pharma based on marketing and distribution rights. During the quarter, BioNTech’s commercial revenues included €4.6 billion gross p...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters